MyFinsight
Home
Blog
About
Maturities of marketable
securities
$10,200K
Net cash (used in)
provided by investing...
$89K
Canceled cashflow
$10,111K
Net increase
(decrease) in cash, cash...
-$37,559K
Canceled cashflow
$89K
Accounts payable and
accrued expenses
$12,544K
Stock-based compensation
expense
$4,901K
Loss (gain) on change
in fair value of...
-$662K
Depreciation
$97K
Noncash lease expense
$93K
Proceeds from exercise of
options
$50K
Purchase of marketable
securities
$9,748K
Purchases of property and
equipment
$363K
Net cash used in
operating activities
-$37,629K
Canceled cashflow
$18,297K
Net cash provided by
financing activities
-$19K
Non-operating income (loss)
$2,312K
Canceled cashflow
$50K
Net loss
-$51,603K
Canceled cashflow
$2,312K
Prepaid expenses and
other current assets
$4,073K
Accrued interest on
marketable securities
-$123K
Amortization (accretion) of
premium (discounts) on...
$70K
Operating lease
liabilities
-$57K
Payment of issuance
costs for private...
$67K
Proceeds from exercise of
warrants
-$2K
Total operating loss
$53,915K
Total research and
development expenses
$44,146K
General and
administrative expenses
$9,769K
Back
Back
Cash Flow
LB PHARMACEUTICALS INC (LBRX)
LB PHARMACEUTICALS INC (LBRX)
source: myfinsight.com